The company's strong revenue growth and high gross margin indicate a successful market adoption of its ARGO HT System. However, the ongoing net losses and the intellectual property litigation with Olink Proteomics AB and Olink Proteomics, Inc. present significant risks. The IPO proceeds will be crucial for funding future growth and research and development, but the company's ability to achieve profitability remains uncertain.
Executive Summary
Alamar Biosciences is conducting an IPO to raise capital, leveraging strong revenue growth (195% YoY) and a growing installed base of its ARGO HT System. The company is positioned in the high-growth advanced proteomics market with a proprietary NULISA technology platform.
Key Financial Metrics
Key Facts
- IPO of 9,375,000 shares with an expected price range of $15.00-$17.00 per share.
- Revenue grew 195% year-over-year to $74.2 million in 2025, with a gross margin of 56%.
- Instrument installed base grew from 36 to 102 units, with average annual consumable pull-through per instrument increasing from $357k to $529k.
- The company has incurred net losses of $47.1 million and $29.8 million in 2024 and 2025, respectively, and expects to continue incurring losses.
- The company is involved in an intellectual property litigation with Olink Proteomics AB and Olink Proteomics, Inc. over patent infringement.
Financial Impact
The IPO is expected to raise approximately $133.2 million in net proceeds, which will be used for general corporate purposes, including working capital, operating expenses, and capital expenditures.
Risk Factors
- The company has incurred net losses since inception and expects to continue incurring losses in the future.
- The company is involved in an intellectual property litigation with Olink Proteomics AB and Olink Proteomics, Inc. over patent infringement.
- The company's limited operating history makes it difficult to evaluate its future prospects and the risks and challenges it may encounter.
Investment Themes
Documents Analyzed
This report is based on 2 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-1/A Filing (Primary) | 0001193125-26-151891 |
| Document: d39680dex1010.htm | 0001193125-26-151891 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 14, 2026 12d ago | 144 | $27.42 | awaiting T+60 | — | $31.93 (−16.45%) |
Oct 14, 2026 12d ago | 144 | $27.42 | awaiting T+60 | — | $31.93 (−16.45%) |
Oct 14, 2026 12d ago | 144 | $27.42 | awaiting T+60 | — | $31.93 (+16.45%) |
Oct 5, 2026 22d ago | Press Release | $32.26 | awaiting T+60 | — | $31.93 (−1.02%) |
Sep 24, 2026 4w ago | Press Release | $32.80 | awaiting T+60 | — | $31.93 (−2.65%) |
Sep 1, 2026 8w ago | 8-K | $30.49 | awaiting T+60 | — | $31.93 (+4.72%) |
Aug 10, 2026 11w ago | 8-K | $36.57 | awaiting T+60 | — | $31.93 (−12.69%) |
Jul 13, 2026 15w ago | Press Release | $27.40 $32.26 | ▲ +17.74% | ▲ +13.74% | $31.93 (+16.53%) |
Jul 10, 2026 15w ago | Press Release | $28.42 $38.13 | ▲ +34.17% | ▲ +31.53% | $31.93 (+12.35%) |
May 8, 2026 24w ago | 8-K | $23.96 $27.11 | ▲ +13.15% | ▲ +8.31% | $31.93 (+33.26%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers